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Raising the bar during early immunotherapy for cancer: simple 
mathematical models may help distinguish temporary vs. ultimate 
progression 
 
Charles F. Babbs, MD, PhD, Weldon School of Biomedical Engineering, Purdue University, 




Background: The apparent success of immunotherapy depends on the duration of follow up, 
sometimes with little evidence of efficacy during the first 4 to 8 months and often some degree 
of “pseudoprogression”.  Differentiating transient pseudoprogression from true progression that 
would require a change in therapy can be challenging.  The present study uses mathematical 
modeling and simulation to account for the unique kinetics and delayed clinical effects of 
immunotherapy and suggests improved approaches to predict efficacy and patient response from 
imaging studies. 
Methods: A mathematical model of tumor cell-immunocyte interaction is exercised to simulate a 
large number of individual patients and to derive surrogate endpoints for success or failure from 
the ratio of tumor diameter at 2, 4, 6, 8, 10, or 12 months follow up to initial tumor diameter.  
The simplified predator-prey model includes 4 lumped parameters: net tumor growth rate, g; 
immune cell killing efficiency, k; immune cell signaling, ; and immune cell half-life decay, μ.  
Differential equations, dT/dt = gT – kL and dL/dt = LT – μL, for numbers of tumor cells, T, 
(the prey) and immunocytes, L, (the predators) are solved numerically as functions of time, t , 
with ranges of g, k, , and initial conditions estimated from clinically available data.  Tumor 
diameters, d, are proportional to the cube root of T + L.  Apparent progression is defined when 
the time-varying diameter ratio, d/d0, exceeds a pre-defined, adjustable threshold.  True 
progression is defined as d/d0 > 1 at 24 months follow up or T/T0 > 10 at any time.  
Results:  Depending on initial conditions, the model equations predict either simple or complex 
dynamics, including cyclic increases in tumor cell numbers prior to a population crash to zero, 
apparent cure with late recurrence, and better long-term outcome with initially smaller 
lymphocyte numbers.  Simulations of 4000 such complex cases show that d/d0 > 1.0 at 2 to 6 
months is a poor predictor of true progression, and often signals pseudoprogression.  However, 
raising the bar or threshold for defining progressive disease from d/d0 > 1.0 to d/d0 > 2.0 during 
the first 6 months of immunotherapy and lowering the bar to d/d0 > 0.5 after 6 months can 
eliminate most instances of pseudoprogression and lead to better over-all outcomes.  
Conclusions: Mathematical models can account for the complex dynamics of immune-tumor 
cell interactions that make accurate clinical decisions to continue or discontinue treatment 
difficult.  The present model and approach can be adapted and calibrated to data for different 
types and stages of cancer and help to optimize treatment success. 
 
Keywords:  agent-based model, checkpoint inhibitors, classifier, cutoff, delayed response, 
immune modulation, iRECIST guidelines, kinetics, optimization, predator-prey, 






Kinetics of conventional chemotherapy for cancer are fundamentally different from those of 
immunotherapy(3, 33, 42).  In conventional chemotherapy cell kill happens initially and rapidly, 
until most susceptible cells are killed or toxic side effects supervene.  Toxicity to normal tissues 
is severe and dose related, and the maximal therapeutic effect happens very near the maximum 
tolerated dose.  Both therapeutic and toxic effects are related to tissue and blood concentrations 
of the drug, as described by classical pharmacokinetics.  These features are very much different 
from those of immunotherapy for cancer, as summarized, for example, by Hoos(21).   
 
In immunotherapy treatment effect is not proportional to toxicity, dose, schedule, or blood levels 
of drug.  The optimal biologic dose is often not the maximum tolerated dose.  Cell kill grows 
exponentially with time, as immunocyte numbers grow, beginning at a low level and ultimately 
reaching a crescendo with a sudden crash in tumor cell numbers.  Early tumor shrinkage is not a 
consistent predictor of survival. Instead, clinical benefits can be delayed and can occur after an 
apparent increase in tumor tissue volume, which would be classically characterized as 
progression, and which would likely lead to discontinuation or to change in approach before any 
benefits are realized.  This initial surge in tumor burden, followed by tumor shrinkage, has been 
termed “pseudoprogression”(7, 33). 
 
Such differences in kinetics and toxicity require a new therapeutic mindset in evaluating whether 
a treatment is working(3), as well as a new conceptual approach to clinical trial design(18, 22).  
In particular, determining the end point of successful therapy may require more patience, more 
tolerance of modest early tumor growth, and more time for observation to determine if the 
immunotherapy is actually working.  Such tolerance of continued tumor growth is concerning for 
physicians and patients accustomed to ordinary chemotherapy.  Better knowledge of the kinetics 
of immunotherapy can help both physicians and patients understand the delayed nature of tumor 
necrosis in a course of immunotherapy and avoid the temptation to quit too soon.   
 
Accordingly, there is a need for new guidelines to distinguish temporary progression from 
ultimate progression in immunotherapy of cancer, both in clinical trials and in daily clinical 
practice.  Already, the virtues of such innovative guidelines have been discussed(36) in terms of 
“raising the bar” for the definition of progressive disease in trials of immunotherapy in order to 
better identify patients with previously unrecognized benefit, despite delayed responses.  
Although cancer biology and immune system biology are exceedingly complex(4), in some cases 
simplifying such a problem in an abstract way can make it easier to solve.  At zero risk to 
patients and essentially zero cost, mathematical models can describe cell kinetics in a rigorous, 
quantitative way(15, 24).  By focusing on crucial factors and deliberately disregarding secondary 
effects, a mathematical models can provide useful descriptions of a complex biological 
processes.  Accordingly, the goal of the present study is to examine results of mathematical 
simulations of immunotherapy for cancer in large numbers of different patients to identify 








Previously, ordinary differential equation models similar to those used in ecology(6) and 
epidemiology, in which cells are considered as individuals in interacting populations, have led to 
important insights for cancer research and clinical practice(2, 15, 19, 25, 26).  The present paper 
describes mathematical modeling of the time histories of tumor growth and shrinkage during 
immunotherapy to identify patterns during the first 12 months of follow up that distinguish 
effective from futile therapy.  The research methods include the following steps. 
 
1. Implement a previously published and simplified kinetic model of immunotherapy 
 
2. Develop a Monte Carlo technique for simulation of a large series of clinical cases, in 
which imaging data for each case during the early months of follow up are correlated 
with ultimate outcome at two years 
 
3. Specify typical values of model parameters that can be modified, based on clinical 
knowledge and data, for different cancer types and stages 
 
4. Define appropriate ranges of model parameters and statistical sampling methods 
 
5. Calculate time histories of tumor growth at 2, 4, 6, 8, 10, and 12 months follow up for 
many individual patient simulations 
 
6. Construct histograms of diameter ratios at each follow up time for cases of either ultimate 
success or ultimate failure (true progression) at 24 months 
 
7. Test possible time-varying “raised bars” for the definition of apparent progression and 






Part 1. Kinetic model of immunotherapy 
 
As previously described in detail(3) one can represent mathematically the predator-prey 
dynamics of immunotherapy for a population of growing tumor cells (the prey) that are killed 
upon contact with cytotoxic immune cells (the predators).  Each population is considered to 
function collectively.  Although the actual populations of tumor and immune cells have diverse 
players with distinct capabilities; at the population level, the outcome of the contest between 
predators and prey can be represented in terms of the balance of power between [prey population 
size  average growth rate] versus [predator population size  average killing effectiveness]. 
 
Let T denote the number of tumor cells and L denote the number of immune cells (lymphocytes 
and activated macrophages).  The rate of change in tumor cell numbers (dT/dt) as a function of 
time, t , is increased by the net growth rate and decreased by immune mediated cell killing.  The 
rate of change in immune cells (dL/dt) is increased by lumped tumor-lymphocyte interactions 
and signaling, and decreased by spontaneous lymphocyte death.  Two equations describe the 










= λTL − μL .          (2) 
 
Constant, g , represents net tumor cell growth minus non-immune mediated cell death. Constant, 
k, represents the average killing effectiveness of all immune cells in the predator “army”.  
Constant,  , represents positive feedback of cell-cell signaling on lymphocyte recruiting, for 
example from release of tumor antigens or from release of cytokines by active lymphocytes.  
Constant, μ , represents spontaneous death and emigration of immune cells.  Equation (1) 
describes the net replication rate in absence of tumor immunity, minus the rate of killing by 
immunocytes.  Equation (2) describes the recruitment of immune cells from cell-cell signaling, 
minus the spontaneous death of immune cells.  As pointed out by Agur(2) the underlying kinetics 
depend on three major factors: the size of the tumor cell population, T, the size of immune cell 
population, L, and the strength of the interactions between the two populations, k and .  The 
lumped interaction term, , includes multiple effects in aggregate, for example changes 
expression of histocompatibility complex antigens by tumor cells, which may weaken their 
detection by cytotoxic lymphocytes, as well as the physical ability of immune cells to penetrate 
the tumor, as in the case of the blood brain barrier in admitting only activated lymphocytes or 





Initial conditions describe the state of the tumor at the time of diagnosis.  T0 is the size of the 
initial pre-treatment tumor cell population, and T(t)/T0 represents the fraction of the initial tumor 
cell mass remaining at time, t , after treatment is begun.  To specify initial conditions, the 
number of lymphocytes is also normalized by the initial number of tumor cells, so that L0/T0 
represents the initial immune cell population within the tumor.   
 
Examination of limiting cases helps to clarify how the model works.  When t = 0, then T = T0 . 
When k = 0 (no tumor cell killing), dT/dt = gT, dT/T = gdt, and by integration,  T = T0e
gt with 
unopposed tumor growth.  When  = 0 there is initial tumor cell killing by the original L0 
lymphocytes, but no recruiting of additional immune cells.  In this case, the immunocytes decay 
exponentially so that L = L0e
−μt, and in turn, dT/dt = gT − kL0e
−μt , with only a transient dip 
in tumor cell growth. 
 
An interesting and useful special case is that of an unstable steady-state, in which the tumor 
neither grows nor shrinks in size.  This condition represents a stalemate with zero net growth in 
either the immune cell population or the tumor population.  Then 
dT/T0
dt
= 0 = g − k
L0
T0
 , so that k 
= gT0/L0.  Also, at stalemate 
dL
dt
= λL0T0 − μL0 = 0, so that T0 = μ.  These relationships help to 
simplify estimation of model parameters from clinically available data, as shown in Part 3 below 
for a generic solid tumor model.  To model histories of tumor growth or shrinkage, Equations (1) 
and (2) are integrated numerically using the simple Euler method, implemented, for example, in 
Visual Basic code within an Excel spreadsheet, using a sufficiently small value of t , such as 
0.001 day, a typical run time on a laptop computer being 0.3 sec per individual patient.  
 
 
Part 2. Monte Carlo technique for simulation of a clinical trial 
 
By accumulating a very large number of simulated cases using Equations (1) and (2) with 
different parameter sets, one can use Monte Carlo simulations as a flight simulator for testing 
classification rules.  The values of the various model parameters in each case are selected from 
probability distributions representing ranges of values expected in a particular patient population, 
including both failed and successful treatments.  Here, for any one simulation, a sample is 
selected from a uniform random distribution ranging from a chosen lower limit to a chosen upper 
limit for each parameter g, k, , mu, and T0/L0.  Specification of these limits is explained in Part 
4.  A sample of 4000 simulated cases was sorted into classes representing “success” and “failure” 
or ultimate progression.  The definition of success was (T/T0 <1 and dT/dt <= 0), representing 
either tumor elimination, continuing tumor shrinkage, or durable stable disease at 24-month 
follow up.  For clinical realism, success also required that T/T0 not exceed 10 at any time during 
the simulation.  This limit is in lieu of the “carrying capacity” constant, K, of Agur(26).  Any 





Part 3. Method for evaluating typical model parameters 
 
Estimation of g. One way to estimate the tumor growth rate in a clinical setting is to assume that 
typical cancers are held in check, compared to more aggressive ones, at least partially by 
immune mechanisms, as suggested by clinical data on the emergence of tumors during 
immunosuppressive therapy for organ transplants(13, 37), as well as by the correlations of tumor 
associated lymphocyte numbers with clinical prognosis(14, 17, 27).  In this case one can estimate 
the net growth rate, g, in the absence of immune mediated cell killing, from the doubling time of 
tumors of a given cell type in immunosuppressed patients.  For minimally immunogenic tumors 
dT/dt  gT, or dT/T  gdt, from which, after integration, T/T0  e
gt.  For doubling time t2, in these 
selected patients it follows that 2 ≈ egt2, or g   ln(2)/t2  0.69/ t2.  For example, if tumors of a 
particular cell type in relatively immunosuppressed patients double in volume in 170 days after 
diagnosis, then we would have g = 0.004/day.  This value is a starting point for our 
representative general model.  It can be modified, as desired, for particular cancer types and 
patient populations going forward. 
 
Estimation of k.  For the equilibrium condition dL/dt = 0 we must have k = g/L0.  For example, if 
g = 0.004 /day, and L0 = 0.001, then k = 4 tumor cells killed per lymphocyte per day.  From 
considerations of practical biology a lymphocyte can only kill a handful of tumor cells per 
day(9).  Hence values of 1 < k < 10 are reasonable. 
 
Estimation of L0/T0. Parameter L0/T0 can be obtained from biopsies of human tissue, as 
determined by quantitative microscopic analysis, flow cytometry, or histochemistry of excised 
tumors or biopsy specimens.  Lymphocytes are microscopically detectable in many tumors(14, 
17, 27).  Previous simulations(3) suggest that values of L0/T0 can vary over many orders of 
magnitude and still result in successful tumor elimination by immunotherapy.  Accordingly, this 
parameter is important to study over a wide range of values to represent the overall variability of 
cytokinetics during immunotherapy, especially in the setting of prior conventional 
chemotherapy. 
 
Estimation of μ.  Normal biology and clinical experience set limits on the value of lymphocyte 
decay, μ.  The offset time for moderate to severe viral infections, which are combated by cellular 
immunity, is on the order of about one week.  The exponential decay of the induration of a PPD 
(purified protein derivative) test for tuberculosis, mediated by cellular immunity, is also a few 
days to one or two weeks(38).  Thus in the absence of stimulation (LT = 0) we would have 
dL/dt = –μL or , L/L0  e
–μt .  For half time t1/2, it follows that 1/2 = e−μt1/2, or μ = ln(2)/t1/2  
0.69/ t1/2.  For example, if the offset of a cellular immune response has a half-life of 7 days, then 
μ  0.1/day.   
 
Estimation of .  Using the relationship that at stalemate 
dL
dt
= λL0T0 − μL0 = 0, one can get a 
working estimate of  = μ/T0 .  So, for T0 = 1, representing the relative initial tumor population 
size as in Table 1,  is estimated as 0.1/day.  In this way reasonable mid-range approximations 
for parameters g, L0/T0 ,  μ, and k, and  can be determined from clinical data for particular types 
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of tumors.  In the present Monte Carlo or stochastic models, individual cases were generated by 
randomly varying model parameters from the midrange values at stalemate listed in Table 1. 
 
 
Table 1. Generic model parameters at stalemate with no net tumor growth, 
despite an active immune system 
 
Parameter Value and units Description 
   
T0/T0 1 Relative tumor cell count 
L0/T0 0.001 Relative immune cell count 
g 0.004/day Tumor growth constant with minimal immune response 
k 4/days Immune cell killing effectiveness  
(tumor cells killed/lymphocyte/day) 
 0.1/day/tumor cell Immune cell signaling constant 




Part 4. Ranges of model parameters and statistical sampling 
 
In the present problem there is a need to focus on clinically realistic ranges of parameters g, k, 
L0/T0, , and .  An unrealistically wide range of parameter values, producing many obvious 
successes and many obvious failures would make simulated clinical decision making falsely 
easy.  So, to determine if various possible decision making algorithms might be clinically useful, 
one needs to test difficult to distinguish cases.  The studies presented here allowed variation of 
parameters over a range extending to twice the stalemate values in Table 1.  Uniform probability 
distributions for parameters g, k, L0/T0, , and  were used with upper and lower bounds shown 
in Table 2.  To span the very large range of possible values of L0/T0, covering several orders of 
magnitude, sampling from a uniform distribution of the logarithm of L0/T0 was done.   
 
 
Table 2. Lower and upper limits of model parameters in Monte Carlo simulations  











Parameter Lower limit and units Upper limit and units 
   
g 0.001/day 0.009/day 
k 0.1/day 10/day 
Log10(L0 /T0) -2 -8 
 0.01 days/tumor cell 0.2 days/tumor cell 




Part 5. Tumor diameter changes at 2, 4, 6, 8, 10, and 12 months as predictors of success or 
failure 
 
New guidelines(31) focus on changes in aggregate tumor diameter, d , vs. time as a marker for 
benefit vs. progression.  Tumor diameter can be estimated at follow up by a variety of medical 
imaging methods.  Diameter based measurements are highly precise and provide a standard 
metric for immune-related response(31). The present study uses the growth ratio d/d0 as an easily 
computed mathematical surrogate for average nodule diameter.  Here we can translate cell 
numbers into tumor size using the overall number of tumor cells, T, plus the overall number of 
lymphocytic cells, L in the tumor.  This sum is assumed to be directly proportional to the tumor 
volume (average linear dimension cubed), and the relative diameter, d/d0 , of tumor masses at 
follow up, so that d/d0 is computed as  √(𝑇 + 𝐿)/(𝑇0 + 𝐿0) 
3
.  Simulated data from full two-year 
(24 month) treatment histories are used to find the relationship between d/d0 at 2, 4, 6, 8, 10, and 
12 months and ultimate success or failure at 24 months.   
 
 
Part 6. Histograms of diameter ratios for success and failure 
 
To evaluate the effectiveness of d/d0 as a predictor of success vs. failure, histograms are created 
for d/d0 data at each bi-monthly follow up time during the first year, first for all successful 
treatments and then for all failed treatments.  When the histograms show separation of the two 
populations on the d/d0 axis, then one can set a decision threshold (“bar” or cutoff value) to 
predict failure early.  If the tumor diameter ratio is less than an optimized cutoff value, then 
watchful waiting is in order and success is likely.  However, if the tumor diameter ratio is greater 
than the optimized cutoff value, then failure is more likely, and the patient is better served by a 
change in treatment.  The overall predictive value of this diagnostic test depends on the 
separation of the distributions of d/d0 for successful and failed treatments.   
 
 
Part 7. A raised bar for immunotherapy 
 
The concept of “re-setting the bar” and for defining progressive disease has been advocated in 
the iRECIST guidelines for response criteria in trials testing immunotherapeutics(36).  In the 
present context the bar can be time varying.  As shown, for example, in Results Figure 6, the 
dashed vertical lines correspond to a particular d/d0 cutoff levels at either 2, 4, 6, 8, 10, or 12 
months.  Optimization is done by trial and error and consideration of the value added by a simple 








Variable histories of immunotherapy  
 
Figure 1 illustrates a variety of simulated histories of immunotherapy for the generic tumor 
model of Tables 1 and 2.  Variations in tumor size are represented in terms of the tumor diameter 
ratio d/d0 .  The middle curve, labeled 1.0X, represents the unstable equilibrium model in Table 
1.  Other curves represent large or small deviations from the unstable equilibrium caused by the 
combined, reciprocal alteration of the two most influential model parameters, immune-tumor cell 
interaction, , and tumor growth rate, g.  The monotonically increasing upper curve, labeled 
0.2X, represents a poor outcome scenario in which immune response parameter, , is weakened 
by a factor of 0.2 and cell growth rate, g, is increased by a factor of 1/0.2 = 5.0.  This curve 
describes ineffective treatment with runaway tumor growth.  The monotonically decreasing 
lower curve, labeled 2.0X, represents a good outcome scenario, in which immune response 
parameter, , is strengthened by a factor of 2.0 and cell growth rate, g, is decreased by a factor of 
1/2.0 = 0.5.  This curve represents highly effective treatment.  These clear-cut outcomes bracket 






Figure 1.  Simulated histories of tumor size in terms of diameter ratio, d/d0 , after onset of 
immunotherapy.  The middle curve, labeled 1.0X, represents the unstable equilibrium model 
in Table 1.  Monotonically increasing upper curve, labeled 0.2X, represents a bad outcome, 
and monotonically decreasing bottom curve, labeled 2.0X, represents a rapid cure.  
Intermediate curves represent  10% changes in both tumor growth rate and immune 





















The curve labeled 0.9X in Figure 1 represents only a slight weakening of immune response by 10 
percent and a slight increase of tumor growth by 10 percent, compared to the stalemate 
conditions at 1.0X.  This modest imbalance produces oscillatory behavior.  There is an initial 
growth in tumor cell numbers, which then provokes an increased host response after a phase 
delay.  This modest increase in host response in insufficient to destroy the tumor, however, and 
after a period of shrinkage, it starts to grow again.  This cycle is repeated until a crescendo is 
reached after 1500 days or 50 months that finally provokes a sufficient immune response to 
destroy the tumor.  The oscillation cycle time is about 1 year, and cure is delayed for 4 cycles. 
 
Obversely, the curve labeled 1.1X represents only a slight strengthening of the immune response 
by 10 percent and a slight decrease of tumor growth by 10 percent.  There is an initial decline in 
tumor cell numbers, which causes a subsequent decreased host response and allows for tumor 
regrowth.  This cycle is repeated at 1-year intervals until a crescendo is reached after 4 years that 
eliminates the tumor.  These simulations illustrate how very small changes in the balance of 
factors governing predator-prey dynamics can alter the time course and outcome of 
immunotherapy.  
 
In Figure 2 the interplay of tumor cells and immune cells for two such closely matched battles is 
illustrated in terms of the relative tumor and immune cell numbers.  T/T0 is the ratio of the tumor 
cell count at the indicated time to the tumor cell count at time zero, and L/T0 is the ratio of the 
lymphocyte count at the indicated time to the tumor cell count at time zero.  In Figures 2(a) and 
2(b) when L0/T0 = 0.0008 at time zero, the tumor can grow slightly, disturbing the equilibrium 
initially and provoking a further host response cyclically.  After 1500 days the lymphocyte ratio 
gets just shy of the lethal level near 0.015, but a few tumor cells hang on.  The tumor is not 






    
   (a)       (b) 
 
    
   (c)       (d) 
 
Figure 2.  Histories of tumor and lymphocyte cell numbers, normalized by initial tumor cell 
count T0, for a representative prolonged, back-and-forth struggle between tumor cells and 
immunocytes.  Growing oscillations in cell numbers occur with a cycle length of roughly 1 
year and a phase delay of about 1/6 cycle or 2 months. 
 
In Figures 2(c) and 2(d) L0/T0 = 0.0012, just slightly larger than the unstable stalemate 
equilibrium of 0.001 at time zero.  The tumor shrinks slightly and there are oscillations around 
the equilibrium value of T/T0 = 1.0.  These non-intuitive results demonstrate sizeable oscillations 
with a period of 500 days in which the tumor mass grows to a maximum and then shrinks 
significantly.  The immune response lags the tumor response in phase.  In Figures 2(c) and 2(d) 
the oscillations gradually amplify until around 1800 days.  Then the lymphocyte population 
finally grows beyond the threshold level near 0.015, which is sufficient to win the battle and kill 
the tumor completely. 
 
 
Importance of the initial immune response 
 
There are more anomalies, including the paradoxical result of success at very low L0/T0 = 
0.0000001 (Figure 3). This value is several orders of magnitude less than the value 0.001 at 
steady state equilibrium.  Now the tumor grows freely and quickly at first and doubles in size.  
Then it provokes a suprathreshold immune response that kills the last tumor cell at 264 days.  

















































    
   (a)            (b) 
 
Figure 3.  Time histories of (a) tumor and (b) lymphocyte cell numbers in an extreme case of 
pseudoregression.  Initial immune response is too weak to impact tumor growth, but after 





    
   (a)      (b) 
 
Figure 4.  Time histories of (a) tumor and (b) lymphocyte cell numbers in a rare case of 
partial response followed by extreme pseudoregression and ultimate tumor elimination after 
two years.  
 
In Figure 4 with L0/T0 = 0.00003 (greater than the value in Figure 3) the initial tumor growth 
produces a strong response but not quite sufficient completely destroy the tumor.  Regrowth 
happens until there is more than doubling of T0, whereupon a lymphocyte population well over 1 
in 100 tumor cells rises up to produce a complete cure, but only after 30 months of treatment.  In 
this case the maximal diameter ratio, dmax/d0  √2.5
3
  1.34. 
 
In general, for a tumor model of a particular growth rate, g, success vs. failure is strongly 
influenced by differences in the initial immunocyte population size, L0/T0 , over many orders of 
magnitude.  Figure 5 shows the time course of tumor diameter for the otherwise standard model 















































representing severely immunodeficient vs. strongly immunocompetent individuals.  The models 
predict surprising and paradoxical responses that have also been observed in the clinic (see 
Discussion) and depend on particular kinetic interactions.  The horizontal line labeled L0/T0 = 
0.001 in Figure 5 indicates the stalemate condition of Table 1.  If the initial immune response is 
either strengthened or weakened by one order of magnitude, oscillations over a 2 to 4 year time 
course happen, similar to those in Figure 2.  However, if the initial lymphocyte population is 
reduced by 3 to 7 orders of magnitude, there is initial tumor diameter growth by about 1.3 to 1.5 





Figure 5.  Simulated histories of tumor size after onset of immunotherapy for various values 
of L0/T0 , illustrating paradoxical effects of initial immune cell population size. 
 
 
In the forgoing simulations, the tumor cells are constantly susceptible to cytotoxic cells with no 
development of resistance or tumor escape mechanisms.  The exponential phases of growth are 
not related to tumor cell heterogeneity or evolution of resistant strains(12, 23), but to the 
underlying kinetics of predator-prey equations(5, 6).  With fewer lymphocytes at time zero more 
tumor growth is needed to provoke an intense, and ultimately successful, anti-tumor immune 
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Histograms of successful vs. failed treatments 
 
Figure 6 shows histograms of tumor diameter ratios for failed and successful courses of 
immunotherapy in a heterogeneous set of 4000 simulated patients having variations in model 
parameters, as shown in Table 2.  The figures show the statistical distributions of d/d0 values 
observed at either 2, 4, 6, 8, 10, or 12 months follow up along the horizontal axes and the 
corresponding probability density functions on the vertical axes.  The probability density 
function (pdf) is scaled by sample size, such that the area under each pdf curve is exactly 1.00. 
 
Circles represent d/d0 values for failed treatments, according to the criteria listed previously.  
Squares represent d/d0 values for successful treatments.  At 2 months follow up, most cases show 
little change in diameter with d/d0 near 1, except for a few treated cases with rapid shrinkage and 
d/d0 near zero.  At 4 and 6 months follow up, greater proportions of treated cases shrink toward 
zero diameter.  At 8 and 12 months follow up, most successful cases show tumor regression, but 
a few remain near their original size or larger.  At 8 and 12 months follow up, failed cases show 
a wide range of sizes, with some partially regressing and some cases continuing to grow.  
Importantly, in this particular model the distributions of successful and failed cases begin to 





     
 
 
     
 
 






























































































































Figure 6.  Histograms, scaled as probability density for easy comparison, of simulated 
successful and failed immunotherapy treatments based on predator-prey kinetic Equations (1) 
and (2).  Square data points represent distributions of successful cases of tumor elimination 
within 2 years and circles represent distributions of failed cases of true progressive disease.  
Areas under the curves of all histograms are 1.00.  Dashed lines represent decision thresholds 
for apparent progressive disease using a raised bar strategy, in which the bar is raised to 2.0 
for the first 6 months of follow up and then lowered to 0.5. 
 
 
The vertical dashed lines in Figure 6 represent a simple step-down protocol, in which a decision 
threshold of 2.0 is used for the first 6 months of follow up and then adjusted downward to 0.5 
after 6 months.  In the standard or reference protocol any increase in tumor diameter is 
considered as evidence of progression, with a constant decision threshold for progressive disease 






Compared to conventional chemotherapy, immunotherapy for cancer has very different kinetics 
that involve building an immune response (k and ) from wide-ranging starting conditions.  
Several months are often required for an adequate T cell population explosion and for homing 
and infiltration of the tumor, after which there is therapeutic tumor cell killing.  In clinical 
practice both physicians and patients, who are accustomed to the kinetics of conventional cancer 
chemotherapy, may be tempted to stop too soon.  Better knowledge of immune response kinetics 
may allow better planning of clinical trials and better individual patient care to account for early, 
clinically insignificant progressive disease or “pseudoprogression”(7, 22, 33).  
 
Mathematical models such as the one described here can help to explain the, complex, dynamical 
behavior of anti-tumor immunity(9, 24, 29, 43).  The simplicity of Equations (1) and (2) encodes 
many emergent behaviors in the battle between immunocytes and cancer cells, including 
oscillations in tumor cell numbers, sharp thresholds between failed and completely successful 
therapy, improved success after weakening of anti-tumor response parameters, and initial tumor 
growth as a prelude to early tumor elimination.  The variable histories of changes in tumor size 
simulated here (Figures 1 to 5) and previously(3), are similar to those observed in patients with 
malignant melanoma treated with anti-cytotoxic T lymphocyte-associated protein 4 
immunotherapy (ipilimumab)(22).  Present results suggest that growth or oscillations in tumor 
size after manipulation of the immune system need not imply selective resistance, escape 
mechanisms, or heterogeneity of the tumor cell population.  Some initial tumor growth after 
treatment begins may simply reflect the nature of a predator-prey-like system.  A very small 
initial population of lymphocytes can be sufficient to start a positive feedback cycle that 





The kinetics of Equations (1) and (2) predict interesting apparent paradoxes that may explain 
treatment failures in early trials of immunotherapy.  As shown previously by Babbs(3) and in 
Figure 1, a form of cyclic pseudoprogression can occur in which the tumor diameter alternately 
grows and shrinks for several cycles prior to a final stage of growth, which is followed by 
massive tumor cell kill.  Such swings are an expected mathematical property of negative 
feedback control and not necessarily a sign of an incorrect hypothesis, sloppy technique, or 
human error.  The rare cases in which tumor cell populations oscillate with increasing peak 
values are reminiscent of the phenomenon of concomitant tumor immunity mediated by a CD-8 
T-cell response, in which challenge with a second tumor implant of the same type can stimulate 
immune rejection(16).  Such unpredictability of dynamic interactions between immune response 
and tumor may mean that personalized patient specific strategies will be needed to achieve 
maximal success.  Here computer simulations and models can help. 
 
The concept of raising the bar for definition of progressive disease may provide practicing 
clinicians and their patients with useful guides to monthly management of immune therapy and 
the necessary encouragement to patiently wait for the immune treatment to work in its own 
characteristic way.  Necessary data are tumor size vs. time curves from imaging studies that are 
already recommended for follow up in immunotherapy(22, 31).  Aggregation of d/d0 data from 
multiple imaging findings can reduce the average measurement error or “noise”, which declines 
as a function of 1/√𝑛 , where  n  is the number of tumor nodules measured.  By monitoring 
tumor diameter growth versus time and using a raised threshold for defining progression during 
the first six months of follow up, one can accommodate expected initial growth in tumor size, as 
the lymphocytic response grows.  This simple adjustment eliminates many false alarms signaling 
progressive disease, which in the setting of conventional chemotherapy would be of concern.  
Here a “raised bar” to 2.0 times original diameter (larger than the 1.2 threshold value 
recommended by Nishino et al.(31)) is shown to have a roughly optimal result on prediction 
accuracy, with little downside cost. 
 
 
Limitations and future work 
 
The present model includes only two differential equations and a handful of parameters.  This is 
clearly an oversimplification.  The complexity of immune mechanisms is well known(32).  There 
are a host of T cell types, T cell exhaustion, pro-tumorigenic subsets of immune cells, 
checkpoints and checkpoint inhibitors, interactions with neutrophils and macrophages, and 
interactions with dendritic cells and myeloid-derived suppressor cells resulting in positive and 
negative feedback loops within the immune system, to name a few(7).  Yet what is remarkable 
from the present study is how just two ordinary differential equations with lumped parameters 
can mimic the kinetics of immunotherapy of cancer to a reasonable degree--perhaps a rare case 
of the “less is more” principle. 
 
Different initial levels of a raised bar may apply to different tumor types and stages.  The present 
study focuses on one generic cancer type to illustrate proof of concept.  However, the model and 
approach described here may well be applicable across a wide range of cancer types, as 
suggested by Seymour(36).  Model parameters can be adjusted to fit different malignant 
diseases.  Further, there is the added potential for tuning the parameters to make of the present  
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model patient specific.  The value of g can be customized based on the patient’s individual 
history.  The value of L0/T0 can be customized based on individual biopsy results(10, 11, 28, 39).  
Perhaps in vitro tests could be done from biopsy material to estimate constants k and .  
Personalized values of  might be estimated, based on specific biomarkers and adjusted for 
various immunotherapy combinations.   
 
Here a general mathematical model is developed to describe the basic time-varying relationships 
of cancer, immunity, and immunotherapy.  In the future patient specific parameters can be 
substituted for the general ones to create truly personalized models using Equations (1) and (2) in 
which the parameters are time-varying and adjusted to reflect changes in dosage, the use of 
adjuvants, or evolution of resistant tumor cell lines, combinations of conventional chemotherapy 
and immunotherapy(1, 8, 15), combinations of radiation and immunotherapy(18), as well as 
variability of cancer types and stages, prior treatments, and evolving mutations(40), conventional 
chemotherapy or radiation followed by immunotherapy(20, 41), targeted radiation to specific 
tumor masses that spares systemic damage to the patient’s immune system, dose fractionation 
schemes, occasional drug holidays, etc.  Adoptive immunotherapy(24, 30, 34), for example, can 
be simulated by a boost in L0.  Adjunctive treatment with immune modifiers such as 
imiquimod(35) can be represented by a boost in .  Another strategy to increase  might be to 
reduce the level of suppressive cells (Treg and myeloid-derived suppressor cells) (1).  
Supplemental radiation treatment can be represented approximately by temporarily replacing the 
positive growth constant, g, with a negative value, so that each cell cycle would then lead to 
death rather than replication.  Many such scenarios are open to investigation.  The present model 
might help to predict especially promising ones for future laboratory or clinical testing. 
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